Group 1: Financial Performance - The company's main revenue significantly declined in Q4 2024 due to macroeconomic factors, industry adjustments, and ongoing procurement policies [2] - The company has implemented measures to enhance profitability, market competitiveness, and sustainable development [2] Group 2: Research and Development - The company has launched several competitive products, including the CS-690 automatic urine biochemical analyzer and the CM-640 automatic chemiluminescence immunoassay analyzer [3] - Focus on AI-driven solutions in urine analysis to improve diagnostic accuracy and efficiency [3] Group 3: Cash Flow Management - A dynamic tracking mechanism has been established to accelerate accounts receivable collection and optimize supplier payment terms [6] - Multiple initiatives are in place to improve cash flow by optimizing production processes and controlling daily expenses [6] Group 4: Market Strategy and Management - The company has developed a market value management system linked to executive performance assessments [6] - Plans to fully integrate with China Resources for risk management and business control, leveraging the brand for growth opportunities [6] Group 5: Future Outlook - The company aims to focus on reagent volume growth as a core business direction for 2025 [6] - Plans to enhance management of accounts receivable, cash flow, and inventory, while ensuring stable and healthy development [6] Group 6: International Trade Impact - The expected impact of U.S. tariffs on the company's exports is minimal, with only about $150,000 projected in 2024, representing a small percentage of total revenue [7] - The company has established a diverse international market presence, exporting to approximately 125 countries and regions [7]